Prostatic Neoplasms: Soulie M

Soulie M, Beuzeboc P, Richaud P, Villers A, Kassab-Chahmi D, Bataillard A, Anonymous00082, Anonymous00083. · Comité rédacteur SOR, INCA, FNCLCC, La Ligue, FHF FNCHRU, FFC et AFU. · Prog Urol. · Pubmed #17633990 No free full text.

Abstract: This paper is based on the bulletin of synthesis 2005. Management of non metastatic prostate cancer. Recommendations for clinical practice of the French Urologial Association and the National Federation of Anticancer Centers.

Villers A, Pommier P, Bataillard A, Fervers B, Bachaud JM, Berger N, Bertrand AF, Bouvier R, Brune D, Daver A, Fontaine E, Haillot O, Lagrange JL, Molinie V, Muratet JP, Pabot du Chatelard P, Peneau M, Prapotnich D, Ravery V, Richaud P, Rossi D, Soulie M, Anonymous00438, Anonymous00439. · CHRU Hôpital Huriez, Lille, France. · Br J Cancer. · Pubmed #12915903 links to  free full text

This publication has no abstract.

Cornud F, Villers A, Mongiat-Artus P, Rebillard X, Soulie M, Anonymous00034. · Centre d'imagerie de Tourville, 19, avenue de Tourville, 75007 Paris, France. · Prog Urol. · Pubmed #18971104 No free full text.

Abstract: Prostate magnetic resonance imaging (MRI) has taken advantage of recent technological developments that increase the field of its indications. Available improvements concern functional MRI based on dynamic MRI (after intravenous injection of gadolinium), diffusion-weighted imaging and, possibly, spectroscopy to localise an undiagnosed prostate cancer on a first series of biopsies and differentiate tumors of significant volume from indolent or latent tumors. The combination of dynamic MRI and diffusion-weighted imaging seems to be the most accurate for the time being. An optimal accuracy to assess local tumor staging can only be obtained with the surface endorectal coil. Future advances concern lymph node extension following an intravenous injection of iron particles and detection of bone metastases by whole-body MRI.

Rebillard X, Gelet A, Davin JL, Soulie M, Prapotnich D, Cathelineau X, Rozet F, Vallancien G. · Clinique Beausoleil, Montpellier, France. · J Endourol. · Pubmed #16053358 No free full text.

Abstract: The literature concerning the efficacy and safety of transrectal high-intensity focused ultrasound (HIFU) for the treatment of localized prostate cancer still comprises a relatively small number of articles. The main studies have been published by four teams using an apparatus available in Europe for several years. The recently presented results of the European Multicentre Study and the study by Gelet and associates based on 242 patients with a follow-up of more than 1 year show that HIFU is a valid alternative for the management of welldifferentiated and moderately differentiated localized prostate cancer with an initial PSA </=15 ng/mL in men with a life expectancy >10 years. In two studies, the combination of transurethral resection of the prostate and HIFU limited the risk of postoperative urinary retention without inducing a higher complication rate. In a series of patients presenting recurrence after external-beam radiotherapy, HIFU was found to be a useful therapy, with >80% negative biopsies. The best indications for HIFU are men over the age of 65, those who are not candidates for radical prostatectomy, obese patients, or patients with comorbidities likely to make surgery more difficult. The learning curve for this technique is relatively short, between 10 and 15 patients, for urologists experienced in transrectal ultrasonography. One of the advantages of HIFU is that it can be repeated in the case of recurrence or to re-treat a prostatic site, it involves no radiation, and patients do not suffer from long-term irritative urinary symptoms.

Huyghe E, Delannes M, Wagner F, Delaunay B, Nohra J, Thoulouzan M, Shut-Yee JY, Plante P, Soulie M, Thonneau P, Bachaud JM. · Department of Urology and Andrology, University Hospital, CHU Rangueil, Toulouse, France. · Int J Radiat Oncol Biol Phys. · Pubmed #19362236 No free full text.

Abstract: PURPOSE: Ejaculatory function is an underreported aspect of male sexuality in men treated for prostate cancer. We conducted the first detailed analysis of ejaculatory function in patients treated with permanent (125)I prostate brachytherapy for localized prostate cancer. PATIENTS AND METHODS: Of 270 sexually active men with localized prostate cancer treated with permanent (125)I prostate brachytherapy, 241 (89%), with a mean age of 65 years (range, 43-80), responded to a mailed questionnaire derived from the Male Sexual Health Questionnaire regarding ejaculatory function. Five aspects of ejaculatory function were examined: frequency, volume, dry ejaculation, pleasure, and pain. RESULTS: Of the 241 sexually active men, 81.3% had conserved ejaculatory function after prostate brachytherapy; however, the number of patients with rare/absent ejaculatory function was double the pretreatment number (p < .0001). The latter finding was correlated with age (p < .001) and the preimplant International Index of Erectile Function score (p < .001). However, 84.9% of patients with maintained ejaculatory function after implantation reported a reduced volume of ejaculate compared with 26.9% before (p < .001), with dry ejaculation accounting for 18.7% of these cases. After treatment, 30.3% of the patients experienced painful ejaculation compared with 12.9% before (p = .0001), and this was associated with a greater number of implanted needles (p = .021) and the existence of painful ejaculation before implantation (p < .0001). After implantation, 10% of patients who continued to be sexually active experienced no orgasm compared with only 1% before treatment. in addition, more patients experienced late/difficult or weak orgasms (p = .001). CONCLUSION: Most men treated with brachytherapy have conserved ejaculatory function after prostate brachytherapy. However, most of these men experience a reduction in volume and a deterioration in orgasm.

Peyromaure M, Rebillard X, Ruffion A, Salomon L, Villers A, Soulie M, Anonymous00115. · Service d'urologie, hôpital Necker, 149, rue de Sèvres, 75015 Paris, France. <> · Prog Urol. · Pubmed #18342148 No free full text.

Abstract: OBJECTIVE: To assess the time-course of plasma testosterone in patients with prostate cancer treated by endocrine therapy. METHODS: A PubMed review of the literature on plasma testosterone and the various endocrine therapies for prostate cancer was performed. RESULTS: The time-course of plasma testosterone varies according to the type of endocrine therapy. The effective castration level, classically considered to be 50 ng/dl, is currently tending to be replaced by 20 ng/dl. Following surgical castration, plasma testosterone reaches effective castration levels within several hours, while with LH-RH agonist therapy, plasma testosterone reaches its trough value after three to four weeks, and remains low for six months after stopping treatment. However, about 15% of patients treated with LH-RH agonists do not achieve effective castration levels. Plasma testosterone remains unchanged or even increases in response to anti-androgens. Plasma testosterone assay is of limited value in routine clinical practice in patients receiving endocrine therapy for prostate cancer, but should be performed in the case of elevation of PSA to ensure that the patient has achieved effective castration levels. CONCLUSION: The correlation between plasma testosterone and progression of prostate cancer is unclear. Other studies are therefore necessary to define the value of plasma testosterone assay in patients treated for prostate cancer.

Yves B, de la Taille A, Chartier-Kastler E, Moreau JL, Davin JL, Mignard JP, Coulange C, Allegre JP, Averous M, Botto H, Coloby P, Conort P, Delmas V, Desgrandchamps F, Fourcade RO, Grall J, Grise P, Kouri G, Le Doze H, Piechaud T, Prunet D, Rambeaud JJ, Rebillard X, Soulie M, Vignes B, Villers A, Anonymous00061. · · Prog Urol. · Pubmed #17489318 No free full text.

Abstract: INTRODUCTION: Information on prostate diseases, including prostate cancer, has been promoted by the Association Française d'Urologie (AFU) for several years, but is developing slowly in France. In 2005, a first communication was targeted to the male public and identified the reasons for the fatalistic attitude of men, and paradoxically, why the prostate incarnates the vulnerability of their sexual capital. As part of a second phase, this article presents the results of a complementary study conducted among general practitioners to identify their expectations and the most appropriate levers to promote screening. MATERIAL AND METHOD: The Ipsos survey company developed a Krisis qualitative protocol in October 2005 (after the first French prostate day on 15 September 2005). Three groups of general practitioners were defined: doctors who are very active in terms of screening, doctors who are uncomfortable with this problem and doctors who systematically refer their patients to urologists. RESULTS: The management of prostate diseases often highlights the ageing process for the patient. The ability to discuss these problems during the consultation depended on the doctor's degree of comfort with this subject, which is related to his/her training and relationships with urologists. To initiate the question of screening, general practitioners involved in this process asked simple questions about everyday practices without being afraid of making jokes or basing their approach on mediatization of the disease. Digital rectal examination is one of the important clinical elements but is not always easy to perform. PSA was found to be an examination that is not always appropriate, characterized by a lack of information on the conditions for ordering this test, its usefulness and its relevance for screening. Ultrasound could be a way of alerting the patient without dramatizing the situation, letting the urologist perform digital rectal examination. Female general practitioners preferred PSA and ultrasound. The doctors surveyed relied on mediatization of prostate diseases, a high level of interactivity with urologists and documents and brochures to be placed in waiting rooms to relay screening messages. CONCLUSION: General practitioners need their authorities, specialists and public health institutions to develop and mediatize andrology in the same way as gynaecology. Urologists play a major supportive role by means of conferences, postgraduate training or AFU invitations.

Irani J, Ravery V, Pariente JL, Chartier-Kastler E, Lechevallier E, Soulie M, Chautard D, Coloby P, Fontaine E, Bladou F, Desgrandchamps F, Haillot O. · University Hospital of Poitiers, France. · J Urol. · Pubmed #12394690 No free full text.

Abstract: PURPOSE: We examine the relationship of nonsteroidal anti-inflammatory drugs and finasteride on the risk of prostate cancer. MATERIALS AND METHODS: Participants in this case control study using a prospective collection of data were drawn from consecutive patients who underwent prostate biopsy at 12 different departments of urology from January 1999 to June 2000. Medication use was assessed by self-questionnaire as well as questions about dietary and lifestyle factors that might be relevant for prostate cancer risk. RESULTS: The study included 639 patients with prostate cancer and 659 cancer-free controls. Univariate analysis showed no significant impact of aspirin and finasteride on prostate cancer risk while the nonaspirin nonsteroidal anti-inflammatory drug users had a lower risk (OR 0.80, 95% CI 0.64-0.99). After adjusting for potential confounders, the protective effect of nonaspirin nonsteroidal anti-inflammatory drugs was no longer significant (OR, 0.84, 95% CI 0.66-1.07), while finasteride showed a significant protective effect (OR 0.58, 95% CI 0.37-0.92). CONCLUSIONS: The results suggest that finasteride could have a chemopreventive role in prostate cancer. While aspirin did not show any impact on prostate cancer risk, the role of nonaspirin nonsteroidal anti-inflammatory drugs warrants further studies.

Huyghe E, Soulie M, Tollon C, Escourrou G, Pontonnier F, Plante P. · Service de Chirurgie Urologique, CHU de Rangueil, Toulouse, France. · Prog Urol. · Pubmed #10370952 No free full text.

Abstract: OBJECTIVES: Study of the value of the free PSA/total PSA ratio in the therapeutic decision concerning prostatic adenocarcinoma, in the case of a single positive biopsy. MATERIAL AND METHODS: The free PSA/total PAS ratio was calculated on serum samples derived from 37 patients with clinically localized prostatic carcinoma and only one positive biopsy, in whom radical prostatectomy was performed. RESULTS: The free PSA/total PSA ratio appeared to be independent of pathological stage and histological prognostic criteria (grade and score, degree of capsular effraction). CONCLUSION: In the case of a single positive biopsy, calculation of the free PSA/total PSA ratio does not appear to provide any decisional criteria in favour of radical prostatectomy.

Soulie M, Beuzeboc P, Irani J, Davin JL. · No affiliation provided · Prog Urol. · Pubmed #16821362 No free full text.

This publication has no abstract.